Literature DB >> 27322592

EMR documentation of physician-patient communication following genomic counseling for actionable complex disease and pharmacogenomic results.

K Sweet1, A C Sturm1, T Schmidlen2, S Hovick3, J Peng4, K Manickam1,5, A Salikhova6, J McElroy4, L Scheinfeldt2,7, A E Toland1, J S Roberts8, M Christman2.   

Abstract

Genomic risk information for potentially actionable complex diseases and pharmacogenomics communicated through genomic counseling (GC) may motivate physicians and patients to take preventive actions. The Ohio State University-Coriell Personalized Medicine Collaborative is a randomized trial to measure the effects of in-person GC on chronic disease patients provided with multiplex results. Nine personalized genomic risk reports were provided to patients through a web portal, and to physicians via electronic medical record (EMR). Active arm participants (98, 39% female) received GC within 1 month of report viewing; control arm subjects (101, 54% female) could access counseling 3-months post-report viewing. We examined whether GC affected documentation of physician-patient communication by reviewing the first clinical note following the patient's GC visit or report upload to the EMR. Multivariable logistic regression modeling estimated the independent effect of GC on physician-patient communication, as intention to treat (ITT) and per protocol (PP), adjusted for physician educational intervention. Counselees in the active arm had more physician-patient communications than control subjects [ITT, odds ratio (OR): 3.76 (95% confidence interval (CI): 1.38-10.22, p < 0.0094); PP, OR: 5.53 (95% CI: 2.20-13.90, p = 0.0017). In conclusion, GC appreciably affected physician-patient communication following receipt of potentially actionable genomic risk information.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  complex disease; counseling; electronic medical record; genetic; genomic; pharmacogenomics; physician-patient communication

Mesh:

Year:  2016        PMID: 27322592      PMCID: PMC5173448          DOI: 10.1111/cge.12820

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  30 in total

1.  Risky business: risk perception and the use of medical services among customers of DTC personal genetic testing.

Authors:  David J Kaufman; Juli M Bollinger; Rachel L Dvoskin; Joan A Scott
Journal:  J Genet Couns       Date:  2012-01-26       Impact factor: 2.537

Review 2.  Personalized genomic information: preparing for the future of genetic medicine.

Authors:  Alan E Guttmacher; Amy L McGuire; Bruce Ponder; Kári Stefánsson
Journal:  Nat Rev Genet       Date:  2010-01-12       Impact factor: 53.242

3.  Charting a course for genomic medicine from base pairs to bedside.

Authors:  Eric D Green; Mark S Guyer
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

4.  Effect of direct-to-consumer genomewide profiling to assess disease risk.

Authors:  Cinnamon S Bloss; Nicholas J Schork; Eric J Topol
Journal:  N Engl J Med       Date:  2011-01-12       Impact factor: 91.245

5.  Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making.

Authors:  Ellen T Matloff; Anne Moyer; Kristen M Shannon; Kristin B Niendorf; Nananda F Col
Journal:  J Womens Health (Larchmt)       Date:  2006-09       Impact factor: 2.681

Review 6.  Patient-physician communication in oncology: what does the evidence show?

Authors:  Anthony Back
Journal:  Oncology (Williston Park)       Date:  2006-01       Impact factor: 2.990

7.  Physician communication and patient adherence to treatment: a meta-analysis.

Authors:  Kelly B Haskard Zolnierek; M Robin Dimatteo
Journal:  Med Care       Date:  2009-08       Impact factor: 2.983

8.  An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons.

Authors:  Amy L McGuire; Wylie Burke
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

9.  Evaluating the utility of personal genomic information.

Authors:  Morris W Foster; John J Mulvihill; Richard R Sharp
Journal:  Genet Med       Date:  2009-08       Impact factor: 8.822

Review 10.  A systematic review of the impact of genetic counseling on risk perception accuracy.

Authors:  Chris M R Smerecnik; Ilse Mesters; Eline Verweij; Nanne K de Vries; Hein de Vries
Journal:  J Genet Couns       Date:  2009-03-17       Impact factor: 2.537

View more
  4 in total

1.  Counselees' Perspectives of Genomic Counseling Following Online Receipt of Multiple Actionable Complex Disease and Pharmacogenomic Results: a Qualitative Research Study.

Authors:  Kevin Sweet; Shelly Hovick; Amy C Sturm; Tara Schmidlen; Erynn Gordon; Barbara Bernhardt; Lisa Wawak; Karen Wernke; Joseph McElroy; Laura Scheinfeldt; Amanda E Toland; J S Roberts; Michael Christman
Journal:  J Genet Couns       Date:  2016-12-05       Impact factor: 2.537

2.  Outcomes of a Randomized Controlled Trial of Genomic Counseling for Patients Receiving Personalized and Actionable Complex Disease Reports.

Authors:  Kevin Sweet; Amy C Sturm; Tara Schmidlen; Joseph McElroy; Laura Scheinfeldt; Kandamurugu Manickam; Erynn S Gordon; Shelly Hovick; J Scott Roberts; Amanda Ewart Toland; Michael Christman
Journal:  J Genet Couns       Date:  2017-03-27       Impact factor: 2.537

3.  Operationalizing the Reciprocal Engagement Model of Genetic Counseling Practice: a Framework for the Scalable Delivery of Genomic Counseling and Testing.

Authors:  Tara Schmidlen; Amy C Sturm; Shelly Hovick; Laura Scheinfeldt; J Scott Roberts; Lindsey Morr; Joseph McElroy; Amanda E Toland; Michael Christman; Julianne M O'Daniel; Erynn S Gordon; Barbara A Bernhardt; Kelly E Ormond; Kevin Sweet
Journal:  J Genet Couns       Date:  2018-02-19       Impact factor: 2.537

4.  Clinician-Stakeholders' Perspectives on Using Patient Portals to Return Lynch Syndrome Screening Results.

Authors:  Diane M Korngiebel; Kathleen M West; Wylie Burke
Journal:  J Genet Couns       Date:  2017-11-21       Impact factor: 2.537

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.